Atea Pharmaceuticals, Inc. revenue

Revenue history

AnnualQuarterly

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atea Pharmaceuticals, Inc.: revenue history, annual

Fiscal year	2020Dec 2020	2021Dec 2021
Revenue	49	351
Growth on the year before	—	+622.5%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Atea Pharmaceuticals, Inc.	$351m	—	—
Pharming Group N.V.	$376m	26.6%	—
Iovance Biotherapeutics, Inc.	$325m	34.5%	—
Sinovac Biotech LTD	$386m	6.8%	66.1%
Arvinas, Inc.	$317m	-15.0%	26.1%
Mannkind Corp	$394m	30.5%	35.5%

Compare with peers

• Pharming Group N.V. revenue
• Iovance Biotherapeutics, Inc. revenue
• Sinovac Biotech LTD revenue
• Arvinas, Inc. revenue
• Mannkind Corp revenue

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atea Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atea Pharmaceuticals, Inc.